Mosaic Window
MOSAIC Window is a curated subset of the groundbreaking MOSAIC dataset, available through K Pro. It includes spatial omics and multimodal data from 60 patients across five cancer types:
BLCA (Bladder Cancer): 15 patients
OV (Ovarian Cancer): 15 patients
GBM (Glioblastoma): 10 patients
DLBCL (Diffuse Large B-cell Lymphoma): 10 patients
MESO (Mesothelioma): 10 patients
This unique resource enables researchers to explore tumor biology at near single-cell resolution, providing detailed insight into tumor and immune cell interactions.
MOSAIC Window Patient Details
BLCA (15 patients):
Stage II and III urothelial carcinoma (one squamous cell carcinoma)
Derived from upfront cystectomies
Most patients receiving complete lymph node dissection
Some treated with adjuvant chemotherapy, chemotherapy, or immune checkpoint inhibitors (ICI) at relapse, with or without radiotherapy
OV (15 patients):
FIGO stage II to IV high grade serous carcinoma
7 baseline, 2 post-NACT, 6 relapse lesions
Treated by upfront or post-NACT interval debulking surgeries and chemotherapy
Additional treatments: Bevacizumab, PARP inhibitors, and ICI in first or later lines
GBM (10 patients):
Glioblastoma as per WHO 2021 definition, all IDH wildtype
6 unmethylated and 4 methylated MGMT promoter samples
Obtained from baseline surgery before standard adjuvant therapy
1 to 3 brain tumor sites, tumor sizes 27 to 80mm diameter
5 patients received Bevacizumab at relapse
DLBCL (10 patients):
Ann Arbor stage III or IV
3 Activated B-cell-like type (ABC), 6 Germinal center B-cell group (GCB), 1 unknown subtype
Obtained at baseline before R-CHOP therapy
Targeted interventions at relapse
MESO (10 patients):
Stage I to III pleural mesotheliomas
5 epithelioid, 5 biphasic
9 baseline biopsies/surgeries, 1 post-NACT sample
4 patients treated by NACT (1 partial response, 3 progressive diseases)
4 patients received anti-PD-1 ICI at relapse (monotherapy or combination with anti-CTLA4)
Last updated
Was this helpful?